For patients who were assigned to the daratumumab group, daratumumab at a dose of 16 mg per kilogram was intravenously administered weekly (on days 1, 8, 15, and 22) for 8 weeks during cycles 1 ...

A retrospective chart review at the Mayo Clinic reviewed eligible patients with multiple myeloma or amyloid light-chain (AL) amyloidosis who received their first dose of daratumumab within the 4 ...

The FDA approved daratumumab and hyaluronidase-fihj for adults with newly diagnosed or relapsed/refractory multiple myeloma.The approval of this product allows for subcutaneous dosing of ...

Treatment with 3 years of subcutaneous daratumumab and hyaluronidase-fihj (Darzalex Faspro) significantly reduced the risk of progression from smoldering to active multiple myeloma without ...

Pieter Sonneveld, MD, PhD, professor of hematology and chair of the Erasmus MC Cancer Institute in Rotterdam, Netherlands, discussed the continued use of subcutaneous daratumumab following initial ...

Information. If NHS organisations wish to consider daratumumab, with lenalidomide and dexamethasone, for treating relapsed or refractory multiple myeloma, they should follow the advice on rational ...

The median relative dose intensity for lenalidomide was 76.2% in the daratumumab group and 91.4% in the control group; 112 patients (30.8%) in the daratumumab group and 83 patients (22.7%) in the ...